Timothy P. Burkholder

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index945citations53works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Analysis(10), Sirtuins and Resveratrol in Medicine(10), Neuropeptides and Animal Physiology(8), Medicinal Plants and Neuroprotection(6), PI3K/AKT/mTOR signaling in cancer(5)

Publications53 total

TableS1, Table S2, Supplementary Methods and Figure Legends from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S2 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S1 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S6 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S3 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Data from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
TableS1, Table S2, Supplementary Methods and Figure Legends from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S6 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Data from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S2 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S1 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Figure S3 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2023Open Access
Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)
Experimental and Molecular Therapeutics·2019
Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)
Cancer Research·2019· 11 cited
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
Bioorganic & Medicinal Chemistry Letters·2018· 16 citedOpen Access
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Molecular Cancer Therapeutics·2017· 45 cited
page 1 of 3Next →

Frequent Co-authors

Sandaruwan Geeganage(19), James R. Gillig(17), Lisa Kays(17), Ming‐Shang Kuo(16), Genshi Zhao(16), Colin F. Green(15), Yu‐Hua Hui(15), Xueqian Gong(15), Shobha Bhattachar(15), Miriam Del Prado(15), Maria-Carmen Fernandez(15), Ken D. Roth(15), Sean G. Buchanan(15), Lourdes Prieto(14), Sucai Dong(14), Bo Tan(14), R.L. Shepard(10), Robert L. Johnson(10), Tao Wang(9), Joshua R. Clayton(8)